Clinical Trials
41 trialsNCT05665530 2026-01-26
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
NCT03268954 2025-10-29
PANTHER
Takeda
Phase 3 Completed
NCT04609826 2025-10-01
DHODH
Janssen Research & Development, LLC
Phase 1 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT02193958 2025-03-19
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1/2 Completed
NCT02268253 2025-01-06
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
NCT02907359 2024-08-27
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT03306264 2024-08-27
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT00043381 2024-08-02
Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT03813186 2024-08-02
Effect of Food on Blood Levels of ASTX727
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT02807272 2024-07-17
CMML/AML
Kura Oncology, Inc.
Phase 2 Completed
NCT02367456 2024-01-19
BRIGHT 1012
Pfizer
Phase 1 Completed
NCT04842604 2023-12-18
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer
Phase 3 Completed
NCT05048498 2023-10-17
Pharmacokinetics, Tolerability and Safety of NEX-18a
Nanexa AB
Phase 1 Completed
NCT05218902 2023-05-31
DIM Vidaza
Bristol-Myers Squibb
Completed
NCT03886831 2023-03-28
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
NCT01736683 2022-10-24
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02610777 2022-09-19
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Takeda
Phase 2 Completed
NCT03263637 2021-10-22
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
AstraZeneca
Phase 1 Completed
NCT01926587 2021-06-16
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Traws Pharma, Inc.
Phase 1/2 Completed
NCT01613976 2020-12-19
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Novartis
Phase 1 Completed
NCT00946647 2020-08-04
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Novartis
Phase 1/2 Completed
NCT01241500 2020-06-30
ONTIME
Traws Pharma, Inc.
Phase 3 Completed
NCT01928537 2020-06-30
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Traws Pharma, Inc.
Phase 3 Completed
NCT02546284 2020-02-28
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Humanigen, Inc.
Phase 1 Completed
NCT02085798 2020-01-27
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Celgene
Completed
NCT01519011 2019-11-12
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine
Celgene
Phase 1 Completed
NCT00528983 2019-11-08
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Celgene
Phase 1 Completed
NCT00761722 2019-11-08
RACE
Celgene
Phase 1 Completed
NCT02891551 2019-07-24
OCEAN
Celgene
Completed
NCT02201329 2018-07-30
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Boehringer Ingelheim
Phase 1 Completed
NCT00171912 2017-02-23
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Novartis
Phase 2 Completed
NCT00642031 2016-08-09
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Prescient Therapeutics, Ltd.
Phase 1 Completed
NCT01464047 2016-04-27
Korean Post-marketing Surveillance for Sprycel®
Bristol-Myers Squibb
Completed
NCT01398462 2016-03-08
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
JW Pharmaceutical
Phase 1 Completed
NCT01192945 2015-11-13
Piaza
iOMEDICO AG
Completed
NCT00283114 2014-12-18
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Seagen Inc.
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00004047 2012-05-16
Chemotherapy in Treating Patients Who Have Hematologic Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00719836 2012-04-20
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
S*BIO
Phase 1/2 Completed